Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent

Inclusion Criteria: All comers" patients: * Male or female patients 18 years or older; * Presence of one or more coronary artery stenoses of 50% or more in a native coronary artery or in a saphenous venous or arterial bypass conduit suitable for coronary stent implantation. * The vessel should have a reference vessel diameter ranging from ≥2.25 mm to ≤4.5 mm (no limitation on the number of treated lesions, vessels, or lesion length); All lesions of the patient must comply with the angiographic inclusion criteria. * The patient (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed. Patient is willing to comply with all protocol-required evaluations. Exclusion Criteria: * Known pregnancy or breastfeeding at time of randomization; * Known contraindication or hypersensitivity to sirolimus, everolimus, cobalt-chromium, or to medications such as aspirin, heparin, bivalirudin, and all of the following four medications: clopidogrel bisulfate, ticlopidine, prasugrel, ticagrelor; * Any PCI treatment within 6 months (\<6 months) prior to the index procedure. * Concurrent medical condition with a life expectancy of less than 12 months. * The patient is unwilling/ not able to return for outpatient clinic at 12 months follow-up. * Currently participating in another trial and not yet at its primary endpoint.